Report Detail
Global Interleukin 1 (IL1) Market Insights, Forecast to 2025
- RnM3028132 |
- 28 February, 2019 |
- Global |
- 127 Pages |
- QYResearch |
- Pharma & Healthcare
The global Interleukin 1 (IL1) market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Interleukin 1 (IL1) market based on company, product type, end user and key regions.
This report studies the global market size of Interleukin 1 (IL1) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Interleukin 1 (IL1) in these regions.
This research report categorizes the global Interleukin 1 (IL1) market by top players/brands, region, type and end user. This report also studies the global Interleukin 1 (IL1) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Optimum Therapeutics LLC
Orphit SAS
Peptinov SAS
AbbVie Inc
Swedish Orphan Biovitrum AB
TWi Biotechnology Inc
XBiotech Inc
Cell Medica Ltd
Exicure Inc
Immune Response BioPharma Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Anacor Pharmaceuticals Inc
Apexigen Inc
R Pharm
Regeneron Pharmaceuticals Inc
Market size by Product
APX-002
Canakinumab
Diacerein CR
IR-1000
Others
Market size by End User
Esophageal Cancer
Fallopian Tube Cancer
Bladder Cancer
Bechcer Disease
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Interleukin 1 (IL1) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Interleukin 1 (IL1) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Interleukin 1 (IL1) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Interleukin 1 (IL1) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Interleukin 1 (IL1) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Interleukin 1 (IL1) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Interleukin 1 (IL1) Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Interleukin 1 (IL1) Market Size Growth Rate by Product
- 1.4.2 APX-002
- 1.4.3 Canakinumab
- 1.4.4 Diacerein CR
- 1.4.5 IR-1000
- 1.4.6 Others
- 1.5 Market by End User
- 1.5.1 Global Interleukin 1 (IL1) Market Size Growth Rate by End User
- 1.5.2 Esophageal Cancer
- 1.5.3 Fallopian Tube Cancer
- 1.5.4 Bladder Cancer
- 1.5.5 Bechcer Disease
- 1.5.6 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Interleukin 1 (IL1) Market Size
- 2.1.1 Global Interleukin 1 (IL1) Revenue 2014-2025
- 2.1.2 Global Interleukin 1 (IL1) Sales 2014-2025
- 2.2 Interleukin 1 (IL1) Growth Rate by Regions
- 2.2.1 Global Interleukin 1 (IL1) Sales by Regions
- 2.2.2 Global Interleukin 1 (IL1) Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Interleukin 1 (IL1) Sales by Manufacturers
- 3.1.1 Interleukin 1 (IL1) Sales by Manufacturers
- 3.1.2 Interleukin 1 (IL1) Sales Market Share by Manufacturers
- 3.1.3 Global Interleukin 1 (IL1) Market Concentration Ratio (CR5 and HHI)
- 3.2 Interleukin 1 (IL1) Revenue by Manufacturers
- 3.2.1 Interleukin 1 (IL1) Revenue by Manufacturers (2014-2019)
- 3.2.2 Interleukin 1 (IL1) Revenue Share by Manufacturers (2014-2019)
- 3.3 Interleukin 1 (IL1) Price by Manufacturers
- 3.4 Interleukin 1 (IL1) Manufacturing Base Distribution, Product Types
- 3.4.1 Interleukin 1 (IL1) Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Interleukin 1 (IL1) Product Type
- 3.4.3 Date of International Manufacturers Enter into Interleukin 1 (IL1) Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Interleukin 1 (IL1) Sales by Product
- 4.2 Global Interleukin 1 (IL1) Revenue by Product
- 4.3 Interleukin 1 (IL1) Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Interleukin 1 (IL1) Breakdown Data by End User
6 North America
- 6.1 North America Interleukin 1 (IL1) by Countries
- 6.1.1 North America Interleukin 1 (IL1) Sales by Countries
- 6.1.2 North America Interleukin 1 (IL1) Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Interleukin 1 (IL1) by Product
- 6.3 North America Interleukin 1 (IL1) by End User
7 Europe
- 7.1 Europe Interleukin 1 (IL1) by Countries
- 7.1.1 Europe Interleukin 1 (IL1) Sales by Countries
- 7.1.2 Europe Interleukin 1 (IL1) Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Interleukin 1 (IL1) by Product
- 7.3 Europe Interleukin 1 (IL1) by End User
8 Asia Pacific
- 8.1 Asia Pacific Interleukin 1 (IL1) by Countries
- 8.1.1 Asia Pacific Interleukin 1 (IL1) Sales by Countries
- 8.1.2 Asia Pacific Interleukin 1 (IL1) Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Interleukin 1 (IL1) by Product
- 8.3 Asia Pacific Interleukin 1 (IL1) by End User
9 Central & South America
- 9.1 Central & South America Interleukin 1 (IL1) by Countries
- 9.1.1 Central & South America Interleukin 1 (IL1) Sales by Countries
- 9.1.2 Central & South America Interleukin 1 (IL1) Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Interleukin 1 (IL1) by Product
- 9.3 Central & South America Interleukin 1 (IL1) by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Interleukin 1 (IL1) by Countries
- 10.1.1 Middle East and Africa Interleukin 1 (IL1) Sales by Countries
- 10.1.2 Middle East and Africa Interleukin 1 (IL1) Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Interleukin 1 (IL1) by Product
- 10.3 Middle East and Africa Interleukin 1 (IL1) by End User
11 Company Profiles
- 11.1 Optimum Therapeutics LLC
- 11.1.1 Optimum Therapeutics LLC Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Optimum Therapeutics LLC Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Optimum Therapeutics LLC Interleukin 1 (IL1) Products Offered
- 11.1.5 Optimum Therapeutics LLC Recent Development
- 11.2 Orphit SAS
- 11.2.1 Orphit SAS Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Orphit SAS Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Orphit SAS Interleukin 1 (IL1) Products Offered
- 11.2.5 Orphit SAS Recent Development
- 11.3 Peptinov SAS
- 11.3.1 Peptinov SAS Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Peptinov SAS Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Peptinov SAS Interleukin 1 (IL1) Products Offered
- 11.3.5 Peptinov SAS Recent Development
- 11.4 AbbVie Inc
- 11.4.1 AbbVie Inc Company Details
- 11.4.2 Company Business Overview
- 11.4.3 AbbVie Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 AbbVie Inc Interleukin 1 (IL1) Products Offered
- 11.4.5 AbbVie Inc Recent Development
- 11.5 Swedish Orphan Biovitrum AB
- 11.5.1 Swedish Orphan Biovitrum AB Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Products Offered
- 11.5.5 Swedish Orphan Biovitrum AB Recent Development
- 11.6 TWi Biotechnology Inc
- 11.6.1 TWi Biotechnology Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 TWi Biotechnology Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 TWi Biotechnology Inc Interleukin 1 (IL1) Products Offered
- 11.6.5 TWi Biotechnology Inc Recent Development
- 11.7 XBiotech Inc
- 11.7.1 XBiotech Inc Company Details
- 11.7.2 Company Business Overview
- 11.7.3 XBiotech Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 XBiotech Inc Interleukin 1 (IL1) Products Offered
- 11.7.5 XBiotech Inc Recent Development
- 11.8 Cell Medica Ltd
- 11.8.1 Cell Medica Ltd Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Cell Medica Ltd Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Cell Medica Ltd Interleukin 1 (IL1) Products Offered
- 11.8.5 Cell Medica Ltd Recent Development
- 11.9 Exicure Inc
- 11.9.1 Exicure Inc Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Exicure Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Exicure Inc Interleukin 1 (IL1) Products Offered
- 11.9.5 Exicure Inc Recent Development
- 11.10 Immune Response BioPharma Inc
- 11.10.1 Immune Response BioPharma Inc Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Immune Response BioPharma Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Immune Response BioPharma Inc Interleukin 1 (IL1) Products Offered
- 11.10.5 Immune Response BioPharma Inc Recent Development
- 11.11 Novartis AG
- 11.12 Omnitura Therapeutics Inc
- 11.13 Opsona Therapeutics Ltd
- 11.14 Anacor Pharmaceuticals Inc
- 11.15 Apexigen Inc
- 11.16 R Pharm
- 11.17 Regeneron Pharmaceuticals Inc
12 Future Forecast
- 12.1 Interleukin 1 (IL1) Market Forecast by Regions
- 12.1.1 Global Interleukin 1 (IL1) Sales Forecast by Regions 2019-2025
- 12.1.2 Global Interleukin 1 (IL1) Revenue Forecast by Regions 2019-2025
- 12.2 Interleukin 1 (IL1) Market Forecast by Product
- 12.2.1 Global Interleukin 1 (IL1) Sales Forecast by Product 2019-2025
- 12.2.2 Global Interleukin 1 (IL1) Revenue Forecast by Product 2019-2025
- 12.3 Interleukin 1 (IL1) Market Forecast by End User
- 12.4 North America Interleukin 1 (IL1) Forecast
- 12.5 Europe Interleukin 1 (IL1) Forecast
- 12.6 Asia Pacific Interleukin 1 (IL1) Forecast
- 12.7 Central & South America Interleukin 1 (IL1) Forecast
- 12.8 Middle East and Africa Interleukin 1 (IL1) Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Interleukin 1 (IL1) Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Interleukin 1 (IL1) . Industry analysis & Market Report on Interleukin 1 (IL1) is a syndicated market report, published as Global Interleukin 1 (IL1) Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Interleukin 1 (IL1) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
